Merck secures fifth PTAB victory against Halozyme MDASE patents
AI Summary- MSD secured a fifth PTAB decision invalidating Halozyme's MDASE-related patent.
- September 2: PTAB found claims 1, 2, 6–15 and 17–30 unpatentable.
- Five MSD-filed PGRs have concluded, while roughly ten remain in examination.